Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

By A. Pascual, Thierry Calandra, S. Bolay, T. Buclin, J. Billé, O. Marchetti. Clinical Infectious Diseases, 2008

876 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/6b4e4d02fdef0c2d72be1940477b9e563c65b62c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. D. Kontoyiannis
2. T. Walsh
3. M. Pfaller
4. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. J. Fishman
3. M. Pfaller
4. D. Diekema

Citations in the corpus

• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “tions [117, 118].”
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “drug concentrations but with significant variability; these may be confused with other etiologies of CNS dysfunction including posterior reversible leukoencephalopathy syndrome or calcineurin inhibitor toxicity [217, 224, 227, 232, 233].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, neutral): “has been observed at lower concentrations [39, 75].”
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “If the level is found to be low, then consideration can be given to resuming the earlier drug at a higher dose (CIII) [415,448].”
• General Principles of Antimicrobial Therapy (2011, background): “In some cases, the use of serum drug level monitoring is supported by its beneficial effect on clinical outcomes (eg, voriconazole in the treatment of invasive fungal infections).(24)”
• Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. (2014, background): “73,76,92 Active dosage adjustment to keep serum concentrations , 5.5 mg/L prevents voriconazole-related toxicity.”